What will be the vaccine efficacy of the two-dose Johnson & Johnson Ad26.COV2.S vaccine candidate according to the results of Phase III testing? | Manifold

What will be the vaccine efficacy of the two-dose Johnson & Johnson Ad26.COV2.S vaccine candidate according to the results of Phase III testing?

Basic

3

Ṁ506

Jul 1

85%

chance

1D

1W

1M

ALL

From https://www.metaculus.com/questions/6819/percent-efficacy-of-two-dose-jj-vaccine/ Resolves to PROB matching Metaculus resolution, rounded to nearest whole percentage. i.e. 90.5 would resolve to 91%.

This question is managed and resolved by Manifold.

Get

1,000

and

3.00

Sort by:

Extending close date to match the Metaculus date (which was extended).

Related questions

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?

Will the M72/AS01E tuberculosis vaccine candidate have an efficacy of 50% or higher in the phase 3 trial?

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Will Vaxart’s oral COVID vaccine candidate show at least 75% efficacy in a human challenge trial?

Related questions

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Will the M72/AS01E tuberculosis vaccine candidate have an efficacy of 50% or higher in the phase 3 trial?

Will Vaxart’s oral COVID vaccine candidate show at least 75% efficacy in a human challenge trial?

© Manifold Markets, Inc.•Terms + Mana-only Terms•Privacy•Rules